XML 65 R49.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Fair Value Measurements - Narrative (Details) |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Aug. 04, 2021 shares | Aug. 31, 2023 shares | Oct. 31, 2022 USD ($) | Aug. 31, 2022 shares | Aug. 31, 2021 sale shares | Sep. 30, 2023 shares | Sep. 30, 2022 shares | Sep. 30, 2021 shares | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Sep. 01, 2025 | May 31, 2021 USD ($) | Jan. 31, 2018 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of marketable securities |  |  |  |  |  |  |  |  | $ 588,733,000 | $ 99,706,000 | $ 50,292,000 |  |  |
Available-for-sale, unrealized loss |  |  |  |  |  |  |  |  | 700,000 | 500,000 |  |  |  |
Fair value transfers in or out of Level 1, Level 2 or Level 3 |  |  |  |  |  |  |  |  | 0 | 0 |  |  |  |
Proceeds from issuance Royalty Financing Agreement |  |  |  |  |  |  |  |  | 0 | 150,000,000 | $ 0 |  |  |
Convertible notes |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible senior notes |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 309,100,000
Unamortized debt issuance costs |  |  |  |  |  |  |  |  | $ 11,091,000 | 14,379,000 |  |  |  |
0.75% convertible senior notes due 2028 | Convertible notes |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate (as a percent) |  |  |  |  |  |  |  |  | 0.75% |  |  |  |  |
Convertible senior notes |  |  |  |  |  |  |  |  |  |  |  |  | $ 371,600,000 |
Unamortized debt issuance costs |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  | 15,700,000 |
Original Term Loan balance |  |  |  |  |  |  |  |  |  |  |  |  | 575,000,000 |
1.75% convertible senior note due 2025 | Convertible notes |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate (as a percent) |  |  |  |  |  |  |  |  | 1.75% |  |  |  |  |
Convertible senior notes |  |  |  |  |  |  |  |  |  |  |  |  | $ 203,400,000 |
Unamortized debt issuance costs |  |  |  |  |  |  |  |  | $ 1,100,000 |  |  |  |  | 14,200,000
Original Term Loan balance |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 450,000,000
Royalty Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty maximum |  |  | 1.8 |  |  |  |  |  |  |  |  |  |  |
Royalty Agreements | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty maximum |  |  | 1.9 |  |  |  |  |  |  |  |  |  |  |
Royalty Agreements | ARIKAYCE Global Net Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage |  |  | 400.00% |  |  |  |  |  |  |  |  |  |  |
Royalty Agreements | ARIKAYCE Global Net Sales | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage |  |  |  |  |  |  |  |  |  |  |  | 450.00% |  |
Royalty Agreements | Brensocatib Global Net Sales | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage |  |  |  |  |  |  |  |  |  |  |  | 75.00% |  |
Royalty Agreements | Secured Debt |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance Royalty Financing Agreement |  |  | $ 150,000,000 |  |  |  |  |  |  |  |  |  |  |
Revenue interest payment |  |  | 150,000,000 |  |  |  |  |  |  |  |  |  |  |
Original Term Loan balance |  |  | 150,000,000 |  |  |  |  |  |  |  |  |  |  |
Lenders fees and deal expenses |  |  | 3,600,000 |  |  |  |  |  |  |  |  |  |  |
Proceeds from royalty financing agreement, net |  |  | $ 146,400,000 |  |  |  |  |  |  |  |  |  |  |
Development and regulatory milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted-average probability of reaching milestone, percentage |  |  |  |  |  |  |  |  | 42.00% |  |  |  |  |
Accrued Liabilities, Current |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred consideration |  |  |  |  |  |  |  |  | $ 5,700,000 |  |  |  |  |
Motus Biosciences, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued in acquisition (in shares) | shares | 2,889,367 | 177,203 |  | 171,427 | 171,427 | 177,203 | 171,427 | 2,889,367 |  |  |  |  |  |
Shares issued upon milestone achievements (in shares) | shares | 5,348,572 |  |  |  | 5,348,572 |  |  |  |  |  |  |  |  |
Motus Biosciences, Inc. | Development and regulatory milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds of sale of priority review voucher obligated to pay to equity holders, percentage |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |
Potential payout, average sales prices for publicly disclosed sales, percentage |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |
Number of publicly disclosed sales used to determine average sales price owed to equity holders | sale |  |  |  |  | 3 |  |  |  |  |  |  |  |  |
Motus Biosciences, Inc. | First anniversary of closing date |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued in acquisition (in shares) | shares | 184,433 |  |  |  | 184,433 |  |  |  |  |  |  |  |  |
Motus Biosciences, Inc. | Second anniversary of closing date |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued in acquisition (in shares) | shares | 184,433 |  |  |  | 184,433 |  |  |  |  |  |  |  |  |
Motus Biosciences, Inc. | Third anniversary of closing date |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued in acquisition (in shares) | shares | 184,433 |  |  |  | 184,433 |  |  |  |  |  |  |  |  |
AlgaeneX, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued upon milestone achievements (in shares) | shares | 368,867 |  |  |  |  |  |  |  |  |  |  |  |  |
Carrying Value | Recurring basis |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Marketable securities |  |  |  |  |  |  |  |  | 298,100,000 | 74,200,000 |  |  |  |
Deferred consideration |  |  |  |  |  |  |  |  | 5,700,000 | 7,400,000 |  |  |  |
Carrying Value | Recurring basis | 0.75% convertible senior notes due 2028 | Level 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible senior notes |  |  |  |  |  |  |  |  | 565,000,000 |  |  |  |  |
Carrying Value | Recurring basis | 1.75% convertible senior note due 2025 | Level 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible senior notes |  |  |  |  |  |  |  |  | 223,900,000 |  |  |  |  |
Fair Value | Recurring basis | Level 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Marketable securities |  |  |  |  |  |  |  |  | 0 | 0 |  |  |  |
Deferred consideration |  |  |  |  |  |  |  |  | 5,700,000 | $ 7,400,000 |  |  |  |
Fair Value | Recurring basis | 0.75% convertible senior notes due 2028 | Level 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible senior notes |  |  |  |  |  |  |  |  | 665,500,000 |  |  |  |  |
Fair Value | Recurring basis | 1.75% convertible senior note due 2025 | Level 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible senior notes |  |  |  |  |  |  |  |  | $ 240,200,000 |  |  |  |  |

X
- Definition Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated to Pay Equity Holders, Percentage + References No definition available. + Details
Name: | insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage
Namespace Prefix: | insm_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares + References No definition available. + Details
Name: | insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares
Namespace Prefix: | insm_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Deferred Liability + References No definition available. + Details
Name: | insm_BusinessCombinationDeferredLiability
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Debt Instrument, Royalty Payable, Maximum + References No definition available. + Details
Name: | insm_DebtInstrumentRoyaltyPayableMaximum
Namespace Prefix: | insm_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Debt Instrument, Royalty, Stated Percentage + References No definition available. + Details
Name: | insm_DebtInstrumentRoyaltyStatedPercentage
Namespace Prefix: | insm_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Fair Value Level 1, Level 2, Level 3 Transfers, Amount + References No definition available. + Details
Name: | insm_FairValueLevel1Level2Level3TransfersAmount
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders + References No definition available. + Details
Name: | insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders
Namespace Prefix: | insm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds From Royalty Financing + References No definition available. + Details
Name: | insm_ProceedsFromRoyaltyFinancing
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Proceeds From Royalty Financing Agreement, Net + References No definition available. + Details
Name: | insm_ProceedsFromRoyaltyFinancingAgreementNet
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Proceeds Of Sale of Priority Review Voucher Obligated to Pay to Equity Holders, Percentage + References No definition available. + Details
Name: | insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage
Namespace Prefix: | insm_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Weighted Average Probability Of Reaching Milestone + References No definition available. + Details
Name: | insm_WeightedAverageProbabilityOfReachingMilestone
Namespace Prefix: | insm_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2 + Details
Name: | us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + References No definition available. + Details
Name: | us-gaap_ConvertibleDebtFairValueDisclosures
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of the fee that accompanies borrowing money under the debt instrument. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DebtInstrumentFeeAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of the required periodic payments applied to interest. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DebtInstrumentPeriodicPaymentInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D + Details
Name: | us-gaap_DeferredFinanceCostsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of investment in marketable security. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details
Name: | us-gaap_MarketableSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash outflow for purchase of marketable security. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11 + Details
Name: | us-gaap_PaymentsToAcquireMarketableSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=insm_ARIKAYCEGlobalNetSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=insm_BrensocatibGlobalNetSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=insm_AccruedLiabilitiesCurrentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |